CGC
Canopy Growth Corp
NASDAQ: CGC · HEALTHCARE · DRUG MANUFACTURERS - SPECIALTY & GENERIC
$0.93
-0.25% today
Updated 2026-09-11
Market cap
$416.81M
P/E ratio
—
P/S ratio
1.42x
EPS (TTM)
$-0.49
Dividend yield
—
52W range
$1 – $2
Volume
3.3M
WallStSmart proprietary scores
36
out of 100
Grade: D
Sell
Investment rating
4.0
Growth
C6.5
Quality
B2.0
Profitability
F5.0
Valuation
C+4/9
Piotroski F-Score
Moderate
-13.0
Altman Z-Score
Distress
—
Industry rank
—
View all highly rated stocks (75+) →251 stocks currently score above 75
Price targets
Analyst target
$1.23
+32.15%
12-Month target
—
—
Intrinsic (DCF)
—
Margin of safety
—
0 Strong Buy2 Buy6 Hold0 Sell0 Strong Sell
Price chart
Stock snapshot
Strengths
+ Revenue growth 12.50% QoQ
+ Debt/equity 0.40x — low leverage
Risks
- Altman Z -12.96 — distress zone
- Thin margins at -79.20%
- Negative free cash flow $-25.75M
Key financials
Revenue Net Income Free Cash Flow
| Metric | 2023 | 2024 | 2025 | 2026 | TTM |
|---|---|---|---|---|---|
| Revenue | $333.25M | $297.15M | $269.00M | $284.60M | $293.63M |
| Net income | $-3.28B | $-657.27M | $-598.12M | $-262.91M | $-14.58M |
| EPS | — | — | — | — | $-0.49 |
| Free cash flow | $-568.00M | $-285.95M | $-177.03M | $-69.76M | $-25.75M |
| Profit margin | -983.68% | -221.19% | -222.35% | -92.38% | -79.20% |
Recent insider activity
| Date | Insider | Type | Shares | Price |
|---|---|---|---|---|
| 2026-08-24 | STEWART, THOMAS CARLTON | Sale | 2,231 | $1.47 |
| 2026-08-24 | GEDEON, CHRISTELLE | Sale | 13,344 | $1.47 |
| 2026-06-26 | YANOFSKY, THERESA | Sale | 15,054 | $0.92 |
Peer comparison
Smart narrative
Canopy Growth Corp trades at $0.93. Our Smart Value Score of 36/100 indicates the stock is weak. The company scores 4/9 on the Piotroski F-Score. With an Altman Z-Score of -12.96, it sits in the distress. TTM revenue stands at $293.63M. with profit margins at -79.20%.
Frequently asked questions
What is Canopy Growth Corp's stock price?
Canopy Growth Corp (CGC) trades at $0.93, on a P/S of 1.4x. Those multiples show what the market is paying for each dollar of earnings and sales, which is the real starting point for judging whether the price is reasonable.
Is Canopy Growth Corp overvalued?
Canopy Growth Corp carries a Smart Value Score of 36/100 (Grade D), which we rate Sell. That score blends growth, quality, and valuation into one read.
What is the price target of Canopy Growth Corp (CGC)?
The 12-month analyst consensus target is $1.23, about 32.2% above the current $0.93. A consensus target is the average of Wall Street's 12-month forecasts, so it works as a sentiment gauge rather than a guarantee, and it resets with every earnings cycle.
What is Canopy Growth Corp's revenue?
Canopy Growth Corp's trailing twelve-month revenue is $293.63M. Revenue scale anchors the valuation multiples and shows whether growth is reaching the top line, so it is best read alongside margin and growth trends to see if that revenue is getting more profitable over time.
Altman Z-Score?
Canopy Growth Corp's Altman Z-Score is -12.96, which places it in the distress. The Altman Z-Score gauges bankruptcy risk from profitability, leverage, and asset efficiency, and a higher reading points to lower financial distress risk.
Company info
SectorHEALTHCARE
IndustryDRUG MANUFACTURERS - SPECIALTY & GENERIC
CountryUSA
ExchangeNASDAQ
CurrencyUSD
Quick metrics
P/S ratio1.42x
ROE-37.65%
Beta2.43
50D MA$0.97
200D MA$1.08
Shares out0.42B
Float0.42B
Short ratio—
Avg volume3.3M
Performance
1 week-4.63%
1 month-9.05%
3 months-7.23%
YTD-18.62%
1 year—
3 years—
5 years—